RxDoctor Payments Data

Hong Tran, MD

Internal Medicine · Rockledge, PANPI 1558345785

Payments from drug & device makers

$2,981in general payments, 2019–2025

Across 203 payments — averaging $14.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$456
  • Pfizer$343
  • Novo Nordisk$333
  • Astellas Pharma US Inc$224
  • AstraZeneca$224
  • Merck$208
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,83795%
  • Education$1445%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,981 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$161,406
Medicare patients
357
Services billed
1,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin248$275,341
JanuviaSitagliptin Phosphate148$167,404
EliquisApixaban181$154,838
OzempicSemaglutide50$55,302
XareltoRivaroxaban46$47,043
ZegeridOmeprazole/Sodium Bicarbonate14$45,170
TrulicityDulaglutide39$40,326
LinzessLinaclotide39$36,723
FarxigaDapagliflozin Propanediol28$30,032
Breo ElliptaFluticasone/Vilanterol52$26,689
MyrbetriqMirabegron20$16,215
VascepaIcosapent Ethyl30$14,910
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,811
JanumetSitagliptin Phos/Metformin Hcl15$13,106
Atorvastatin Calcium736$10,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$161$275,341248 claims
MerckJanuvia, Janumet, Dulera$208$185,928179 claims
PfizerEliquis$343$154,838181 claims
Novo NordiskOzempic$333$55,30250 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$148$48,09082 claims
Johnson & JohnsonXarelto$129$47,04346 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCZegerid$84$45,17014 claims
AbbVieLinzess, Synthroid$456$42,569113 claims
Lilly USA, LLCTrulicity$163$40,32639 claims
AstraZenecaFarxiga, Symbicort$224$35,79158 claims
Astellas Pharma US IncMyrbetriq$224$16,21520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Rockledge

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →